The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis

References

• Khanna D, Lovell DJ, Giannini E, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis. 2008 May;67(5):703–709. PubMed PMID: 17893248; eng.
   PubMed Web of Science ®Google Scholar
• Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med. 2004 Jan 6;140(1):37–50. PubMed PMID: 14706971.
   PubMed Web of Science ®Google Scholar
• Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum. 1975 May;4(4):351–368. PubMed PMID: 1135634.
   PubMedGoogle Scholar
• Minier T, Guiducci S, Bellando-Randone S, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2014 Dec;73(12):2087–2093. PubMed PMID: 23940211.
   PubMed Web of Science ®Google Scholar
• Bellando-Randone S, Matucci-Cerinic M. From Raynaud’s phenomenon to very early diagnosis of systemic sclerosis – the VEDOSS approach. Curr Rheumatol Rev. 2013;9(4): 245–248. PubMed PMID: 26932288.
   PubMedGoogle Scholar
• Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007 Jun;66(6):754–763. PubMed PMID: 17234652; PubMed Central PMCID: PMCPMC1954657.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001 Jul;28(7):1573–1576. PubMed PMID: 11469464.
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov;65(11):2737–2747. PubMed PMID: 24122180; PubMed Central PMCID: PMC3930146.
   PubMed Web of Science ®Google Scholar
• Koenig M, Joyal F, Mj F, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008 Dec;58(12):3902–3912. PubMed PMID: 19035499.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Pizzorni C, et al. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol. 2000 Jan;27(1):155–160. PubMed PMID: 10648032.
   PubMed Web of Science ®Google Scholar
• Pizzorni C, Giampetruzzi AR, Mondino C, et al. Nailfold capillaroscopic parameters and skin telangiectasia patterns in patients with systemic sclerosis. Microvasc Res. 2017 May;111:20–24. PubMed PMID: 27989404.
   PubMed Web of Science ®Google Scholar
• Baron M, Pope J, Robinson D, et al. Calcinosis is associated with digital ischaemia in systemic sclerosis – a longitudinal study. Rheumatology. 2016 Dec;55(12):2148–2155. PubMed PMID: 27593964; PubMed Central PMCID: PMCPMC5144666.
   PubMed Web of Science ®Google Scholar
• Morardet L, Avouac J, Sammour M, et al. Late nailfold videocapillaroscopy pattern associated with hand calcinosis and acro-osteolysis in systemic sclerosis. Arthrit Care Res. 2016 Mar;68(3):366–373. PubMed PMID: WOS:000371056700012; English.
   Web of Science ®Google Scholar
• Avouac J, Lepri G, Smith V, et al. Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis. Semin Arthritis Rheu. 2017 Aug;47(1):86–94. PubMed PMID: WOS:000407411400010; English.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Herrick AL, Distler O, et al. Nailfold videocapillaroscopic features and other clinical risk factors for digital ulcers in systemic sclerosis: a multicenter, prospective cohort study. Arthritis Rheumatol. 2016 Oct;68(10):2527–2539. PubMed PMID: WOS:000384819400021; English.
   PubMed Web of Science ®Google Scholar
• Smith V, Riccieri V, Pizzorni C, et al. Nailfold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis. J Rheumatol. 2013 Dec;40(12):2023–2028. PubMed PMID: 24128778.
   PubMed Web of Science ®Google Scholar
• Bassel M, Hudson M, Taillefer SS, et al. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology. (Oxford). 2011 Apr;50(4):762–767. PubMed PMID: 21149249
   PubMed Web of Science ®Google Scholar
• Pauling JD, Saketkoo LA, Matucci-Cerinic M, et al. The patient experience of Raynaud’s phenomenon in systemic sclerosis. Rheumatology. (Oxford) 2018 Mar 12 DOI:10.1093/rheumatology/key026 PubMed PMID: 29538754.
   Google Scholar
• Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999 Dec;42(12):2646–2655. PubMed PMID: 10616013; eng.
   PubMedGoogle Scholar
• Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology. 2001 Sep;40(9):1038–1043. PubMed PMID: 11561116; eng.
   PubMed Web of Science ®Google Scholar
• Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994 Feb 1;120(3):199–206. PubMed PMID: 7506013.
   PubMed Web of Science ®Google Scholar
• Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998 Apr;41(4):670–677. PubMed PMID: 9550476; eng.
   PubMedGoogle Scholar
• Black CM, Halkier-Sorensen L, Belch JJ, et al. Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol. 1998 Sep;37(9):952–960. PubMed PMID: 9783759; eng.
   PubMedGoogle Scholar
• Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum. 2002 Sep;46(9):2410–2420. PubMed PMID: 12355489; eng.
   PubMedGoogle Scholar
• Schiopu E, Hsu VM, Impens AJ, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol. 2009 Oct;36(10):2264–2268. PubMed PMID: 19755613.
   PubMed Web of Science ®Google Scholar
• Herrick AL, Van Den Hoogen F, Gabrielli A, et al. Modified-release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 2011 Mar;63(3):775–782. PubMed PMID: 21360507.
   PubMedGoogle Scholar
• Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009 Mar;60(3):870–877. PubMed PMID: 19248104.
   PubMedGoogle Scholar
• Nguyen VA, Eisendle K, Gruber I, et al. Effect of the dual endothelin receptor antagonist bosentan on Raynaud’s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology. 2010 Mar;49(3):583–587. PubMed PMID: 20040526.
   PubMed Web of Science ®Google Scholar
• Denton CP, Hachulla E, Riemekasten G, et al. Efficacy and safety of selexipag in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study. Arthritis Rheumatol. 2017 Dec;69(12):2370–2379. PubMed PMID: 29193819.
   PubMed Web of Science ®Google Scholar
• Sctc,CSRG Walker KM, Pope J, Treatment of systemic sclerosis complications: what to use when first-line treatment fails – a consensus of systemic sclerosis experts. Semin Arthritis Rheu. 2012 Aug;42(1):42–55. PubMed PMID: WOS:000307030300006; English.
   PubMed Web of Science ®Google Scholar
• Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK scleroderma study group: digital vasculopathy in systemic sclerosis. Rheumatology. 2015 Nov;54(11):2015–2024. PubMed PMID: 26116156.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327–1339. PubMed PMID: 27941129.
   PubMed Web of Science ®Google Scholar
• Gladue H, Maranian P, He P, et al. Evaluation of test characteristics for outcome measures used in Raynaud’s phenomenon clinical trials. Arthritis Care Res. 2013 Apr;65(4):630–636. PubMed PMID: 22972592; PubMed Central PMCID: PMCPMC3529989.
   Web of Science ®Google Scholar
• Pauling JD, Shipley JA, Hart DJ, et al. Use of laser speckle contrast imaging to assess digital microvascular function in primary Raynaud phenomenon and systemic Sclerosis: a comparison using the Raynaud condition score diary. J Rheumatol. 2015 Jul;42(7):1163–1168. PubMed PMID: 26034146.
   PubMed Web of Science ®Google Scholar
• Wilkinson JD, Leggett SA, Marjanovic EJ, et al. A multicentre study of validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud’s phenomenon. Arthritis Rheumatol. 2018 Feb; ePublished ahead of print:18. DOI:10.1002/art.40457 PubMed PMID: 29457381.
   PubMed Web of Science ®Google Scholar
• Pauling J, Frech TM, Hughes M, et al. Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. Journal of Scleroderma & Related Disorders. 2018. In press.
   Google Scholar
• Pauling JD, Domsic RT, Saketkoo LA, et al. A multi-national qualitative research study exploring the patient experience of Raynaud’s phenomenon in systemic sclerosis. Arthritis Care Res. ePublished ahead of print. 2017 Nov 21. DOI:10.1002/acr.23475 PubMed PMID: 29473715.
   Google Scholar
• Pauling JD, Saketkoo LA, Domsic RT. Patient perceptions of the Raynaud’s Condition Score diary provide insight into its performance in clinical trials of Raynaud’s phenomenon. Arthritis Rheumatol. 2018 Mar 7. PubMed PMID: 29513932. DOI:10.1002/art.40481
   Google Scholar
• Administration USDoHaHSFaD. Guidance for Industry: patient-reported outcome measures: use in medical product development to support labeling claims 2009 [ cited 2016 Jun 01]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
   Google Scholar
• Pauling JD, Frech TM, Domsic RT, et al. Patient participation in patient-reported outcome instrument development in systemic sclerosis. Clin Exp Rheumatol. 2017 Sep-Oct;106(4Suppl):184–192. PubMed PMID: 28516884.
   Google Scholar
• Roustit M, Blaise S, Millet C, et al. Reproducibility and methodological issues of skin post-occlusive and thermal hyperemia assessed by single-point laser Doppler flowmetry. Microvasc Res. 2010 Mar;79(2):102–108. PubMed PMID: 20064535.
   PubMed Web of Science ®Google Scholar
• Pauling JD, Shipley JA, Harris ND, et al. Use of infrared thermography as an endpoint in therapeutic trials of Raynaud’s phenomenon and systemic sclerosis. Clin Exp Rheumatol. 2012 Mar-Apr;30(2):S103–S115. PubMed PMID: WOS:000304976600017; English.
   PubMed Web of Science ®Google Scholar
• Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud’s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017 Aug;69(8):1661–1669. PubMed PMID: 28426903; PubMed Central PMCID: PMCPMC5529251.
   PubMed Web of Science ®Google Scholar
• Andrigueti FV, Ebbing PCC, Arismendi MI, et al. Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clin Exp Rheumatol. 2017 Sep-Oct;106(4):151–158. PubMed PMID: 28281457.
   Google Scholar
• Shah AA, Schiopu E, Hummers LK, et al. Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. Arthritis Res Ther. 2013 Apr 18;15(2):R54. PubMed PMID: 23597147; PubMed Central PMCID: PMCPMC5011881.
   PubMedGoogle Scholar
• Herrick AL, Murray AK, Ruck A, et al. A double-blind, randomized, placebo-controlled crossover trial of the alpha2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. Rheumatology. (Oxford). 2014 May;53(5):948–952. PubMed PMID: 24489014.
   PubMed Web of Science ®Google Scholar
• Steen V, Denton CP, Pope JE, et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology. 2009 Jun;48(Suppl 3):iii19–24. PubMed PMID: 19487218; eng.
   PubMedGoogle Scholar
• Muangchan C, Canadian Scleroderma Research Group, Baron M, et al. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol. 2013 Sep;40(9):1545–1556. PubMed PMID: 23858045.
   PubMed Web of Science ®Google Scholar
• Nihtyanova SI, Brough GM, Black CM, et al. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2008 Jan;67(1):120–123. PubMed PMID: 17660220.
   PubMed Web of Science ®Google Scholar
• Mihai C, Landewe R, van der Heijde D, et al. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis. 2016 Apr;75(4):681–686. PubMed PMID: 25688073.
   PubMed Web of Science ®Google Scholar
• Mouthon L, Mestre-Stanislas C, Berezne A, et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis. 2010 Jan;69(1):214–217. PubMed PMID: 19221115.
   PubMed Web of Science ®Google Scholar
• Berezne A, Seror R, Morell-Dubois S, et al. Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. Arthritis Care Res . (Hoboken). 2011 Feb;63(2):277–285. PubMed PMID: 20824802
   Web of Science ®Google Scholar
• Guillevin L, Hunsche E, Denton CP, et al. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO registry. Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):71–80. PubMed PMID: 23910613.
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Krieg T, Guillevin L, et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO registry. Ann Rheum Dis. 2016 Oct;75(10):1770–1776. PubMed PMID: 26612339; PubMed Central PMCID: PMCPMC5036212.
   PubMed Web of Science ®Google Scholar
• Smith V, Decuman S, Sulli A, et al. Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? A pilot study. Ann Rheum Dis. 2012 Oct;71(10):1636–1639. PubMed PMID: 22402146.
   PubMed Web of Science ®Google Scholar
• Manfredi A, Sebastiani M, Carraro V, et al. Prediction risk chart for scleroderma digital ulcers: a composite predictive model based on capillaroscopic, demographic and clinico-serological parameters. Clin Hemorheol Micro. 2015;59(2):133–143. PubMed PMID: WOS:000350905500005; English.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Manfredi A, Colaci M, et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum. 2009 May 15;61(5):688–694. PubMed PMID: 19405007.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Manfredi A, Lo MA, et al. Capillaroscopic Skin Ulcers Risk Index (CSURI) calculated with different videocapillaroscopy devices: how its predictive values change. Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):115–117. PubMed PMID: 23557914.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Manfredi A, Vukatana G, et al. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study. Ann Rheum Dis. 2012 Jan;71(1):67–70. PubMed PMID: 21917823.
   PubMed Web of Science ®Google Scholar
• Korn JH, Mayes M,M, Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004 Dec;50(12):3985–3993. PubMed PMID: 15593188.
   PubMed Web of Science ®Google Scholar
• Baron M, Chung L, Gyger G, et al. Consensus opinion of a North American working group regarding the classification of digital ulcers in systemic sclerosis. Clin Rheumatol. 2014 Feb;33(2):207–214. PubMed PMID: 24357325.
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011 Jan;70(1):32–38. PubMed PMID: 20805294; PubMed Central PMCID: PMCPMC3002766.
   PubMed Web of Science ®Google Scholar
• Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol. 2007 Dec;34(12):2423–2430. PubMed PMID: 17985402.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Asano Y, Hatano M, et al. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis. Br J Dermatol. 2012 Feb;166(2):417–421. PubMed PMID: 21848685.
   PubMed Web of Science ®Google Scholar
• Pauling JD. Vasodilation is not the only approach to the management of cutaneous ulceration in systemic sclerosis. Rheumatology. (Oxford) 2017 Sep 01;56(9):1559. . PubMed PMID: 28859324.
   PubMed Web of Science ®Google Scholar
• Herrick AL, Roberts C, Tracey A, et al. Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. Arthritis Rheum. 2009 Mar;60(3):878–882. PubMed PMID: 19248100.
   PubMedGoogle Scholar
• Hughes M, Roberts C, Tracey A, et al. Does the clinical context improve the reliability of rheumatologists grading digital ulcers in systemic sclerosis? Arthritis Care Res . (Hoboken). 2016 Sep;68(9):1340–1345. PubMed PMID: 26748825; PubMed Central PMCID: PMCPMC5006886.
   Web of Science ®Google Scholar
• Giuggioli D, Manfredi A, Lumetti F, et al. Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature. Autoimmun Rev. 2017 Dec;2. DOI:10.1016/j.autrev.2017.11.020. PubMed PMID: 29196241.
   Google Scholar
• Souza EJR, Muller CS, Horimoto AMC, et al. Geographic variation as a risk factor for digital ulcers in systemic sclerosis patients: a multicentre registry. Scand J Rheumatol. 2017;46(4):288–295. PubMed PMID: WOS:000406121700005; English.
   PubMed Web of Science ®Google Scholar
• Tingey T, Shu J, Smuczek J, et al. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res. 2013 Sep;65(9):1460–1471. PubMed PMID: 23554239.
   PubMed Web of Science ®Google Scholar
• Pope J, Harding S, Khimdas S, et al. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian scleroderma research group. J Rheumatol. 2012 Mar;39(3):524–531. PubMed PMID: 22247347.
   PubMed Web of Science ®Google Scholar
• Moinzadeh P, Riemekasten G, Siegert E, et al. Vasoactive therapy in systemic sclerosis: real-life therapeutic practice in more than 3000 patients. J Rheumatol. 2016 Jan;43(1):66–74. PubMed PMID: 26568599.
   PubMed Web of Science ®Google Scholar
• Ruaro B, Sulli A, Smith V, et al. Short-term follow-up of digital ulcers by laser speckle contrast analysis in systemic sclerosis patients. Microvasc Res. 2015 Sep;101:82–85. PubMed PMID: 26142117.
   PubMed Web of Science ®Google Scholar
• Hughes M, Moore T, Manning J, et al. Reduced perfusion in systemic sclerosis digital ulcers (both fingertip and extensor) can be increased by topical application of glyceryl trinitrate. Microvasc Res. 2017 May;111:32–36. PubMed PMID: 28027937; PubMed Central PMCID: PMCPMC5351498.
   PubMed Web of Science ®Google Scholar
• Walker JG, Stirling J, Beroukas D, et al. Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis. Pathology. 2005 Jun;37(3):220–225. PubMed PMID: 16175895.
   PubMed Web of Science ®Google Scholar
• Halachmi S, Gabari O, Cohen S, et al. Telangiectasis in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment. Lasers Med Sci. 2014 Jan;29(1):137–140. PubMed PMID: 23494102.
   PubMed Web of Science ®Google Scholar
• Braverman IM, Ken-Yen A. Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases. J Invest Dermatol. 1983 Dec;81(6):489–497. PubMed PMID: 6417247.
   PubMed Web of Science ®Google Scholar
• Robert-Thomson PJ, Mould TL, Walker JG, et al. Clinical utility of telangiectasia of hands in scleroderma and other rheumatic disorders. Asian Pac J Allergy Immunol. 2002 Mar;20(1):7–12. PubMed PMID: 12125921.
   PubMed Web of Science ®Google Scholar
• Ennis H, Herrick AL, Cassidy C, et al.A pilot study of body image dissatisfaction and the psychological impact of systemic sclerosis-related telangiectases. Clin Exp Rheumatol. 2013;Mar-Apr;31(2 Suppl 76):12–17. PubMed PMID: 23324653.
   Web of Science ®Google Scholar
• Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol. 2010 Jan;37(1):98–104. . PubMed PMID: 19955048; PubMed Central PMCID: PMC3419384.
   PubMed Web of Science ®Google Scholar
• Hetzer S, Buhren BA, Schrumpf H, et al. Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin. Eur J Med Res. 2014 Jan 10;19:2. PubMed PMID: 24410934; PubMed Central PMCID: PMC3902062.
   PubMed Web of Science ®Google Scholar
• Zhang SZ, Xu D, Li MT, et al.Telangiectasia as a potential clinical marker of microvascular lesions in systemic sclerosis patients from EUSTAR data in China. Clin Exp Rheumatol. 2015;Jul-Aug;33(4 Suppl 91):S106–10. PubMed PMID: 26005882.
   Web of Science ®Google Scholar
• Hurabielle C, Avouac J, Lepri G, et al. Skin telangiectasia and the identification of a subset of systemic sclerosis patients with severe vascular disease. Arthritis Care Res. 2016 Jul;68(7):1021–1027. PubMed PMID: 26474084.
   Web of Science ®Google Scholar
• Huang J, Li M, Tian Z, et al. Clinical and laboratory characteristics of systemic sclerosis patients with pulmonary arterial hypertension in China. Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-115–21. PubMed PMID: 25372797.
   Web of Science ®Google Scholar
• Yalcinkaya Y, Pehlivan O, Omma A, et al. The relationship between nailfold capillaroscopic assessment and telangiectasia score with severity of peripheral vascular involvement in systemic sclerosis. Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S92–7. PubMed PMID: 25797836.
   PubMed Web of Science ®Google Scholar
• Tolosa-Vilella C, Morera-Morales ML, Simeon-Aznar CP, et al. Digital ulcers and cutaneous subsets of systemic sclerosis: clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE registry. Semin Arthritis Rheum. 2016 Oct;46(2):200–208. PubMed PMID: 27312381.
   PubMed Web of Science ®Google Scholar
• Giampetruzzi AR, Mondino C, Facchiano A, et al. Association of dermoscopic profiles of telangiectases with nailfold videocapillaroscopic patterns in patients with systemic sclerosis. J Rheumatol. 2013 Sep;40(9):1630–1632. PubMed PMID: 23997004.
   PubMed Web of Science ®Google Scholar
• Gates C, Morand EF, Davis M, et al. Sclerotherapy as treatment of recurrent bleeding from upper gastrointestinal telangiectasia in CREST syndrome. Br J Rheumatol. 1993 Aug;32(8):760–761. PubMed PMID: 8348284.
   PubMedGoogle Scholar
• Murray AK, Moore TL, Richards H, et al. Pilot study of intense pulsed light for the treatment of systemic sclerosis-related telangiectases. Br J Dermatol. 2012 Sep;167(3):563–569. PubMed PMID: 22540211.
   PubMed Web of Science ®Google Scholar
• Dinsdale G, Murray A, Moore T, et al. A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial. Rheumatology. 2014 Aug;53(8):1422–1430. PubMed PMID: 24625502.
   PubMed Web of Science ®Google Scholar
• Caramaschi P, Biasi D, Caimmi C, et al. Digital amputation in systemic sclerosis: prevalence and clinical associations. A retrospective longitudinal study. J Rheumatol. 2012 Aug;39(8):1648–1653. PubMed PMID: 22707610.
   PubMed Web of Science ®Google Scholar
• Kucuksahin O, Ates A, Okoh AK, et al. Treatment resistant severe digital ischemia associated with antiphospholipid syndrome in a male patient with systemic sclerosis. Case Rep Rheumatol. 2014;2014:291382. PubMed PMID: 25110600; PubMed Central PMCID: PMCPMC4119641.
   PubMedGoogle Scholar
• Omair MA, Bookman A, Mittoo S. Digital gangrene in a patient with systemic lupus erythematosus and systemic sclerosis. J Rheumatol. 2012 Sep;39(9):1895–1897. . PubMed PMID: 22942305.
   PubMed Web of Science ®Google Scholar
• Zaima C, Kanai M, Ishikawa S, et al. A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. Jpn J Clin Oncol. 2011 Jun;41(6):803–806. PubMed PMID: 21478179.
   PubMed Web of Science ®Google Scholar
• Wong M, Ranganath VK, Clements PJ. Antineutrophil cytoplasmic antibody-positive digital necrosis in a patient with limited systemic sclerosis. J Rheumatol. 2010 Jan;37(1):214–215. . PubMed PMID: 20040651; PubMed Central PMCID: PMCPMC3038343.
   PubMed Web of Science ®Google Scholar
• Pauling JD, Brown SJ, James J, et al. Vacuum-assisted closure therapy: a novel treatment for wound healing in systemic sclerosis. Rheumatology . (Oxford). 2011 Feb;50(2):420–422. PubMed PMID: 20959357.
   PubMed Web of Science ®Google Scholar
• Harrison BJ, Silman AJ, Hider SL, et al. Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum. 2002 Dec;46(12):3312–3316. PubMed PMID: 12483737.
   PubMedGoogle Scholar
• Herrick AL, Heaney M, Hollis S, et al. Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia. Ann Rheum Dis. 1994 Aug;53(8):540–542. PubMed PMID: 7944641; PubMed Central PMCID: PMCPMC1005396.
   PubMed Web of Science ®Google Scholar